Biopharma | May 06, 2026
Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Subscribe To Our Newsletter & Stay Updated
